MIVI Neuroscience Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference
Primary effectiveness endpoint results show high revascularization rates of 93.9% mTICI 2b/3
Source: dicardiology.com
Stay updated with breaking news from Revascularization System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Primary effectiveness endpoint results show high revascularization rates of 93.9% mTICI 2b/3
/PRNewswire/ -- MIVI Neuroscience, Inc., innovator of next-generation neurointerventional medical devices, today announced that it has completed enrollment in...